There is nothing much more to add to the prior two posts by Bear and Telepanel, they encapsulate how I am sure most of us feel re the COVID trial, financing and general RVX strategic direction or lack there of.

Not that my next comment really amounts to anything, but I have two contacts, one in the Pharma industry who has been slightly intrigued by RVX, but was never enmoured with the design of the trials and another who has had significant involvement with the AHA conferences for many years and has not given me more than sneers towards my RVX investment and their trials. Both today for the first time raised their eyebrows when they saw Cell published the study and asked if the stock ran? Although pointed out today on the board, I dont think us non-science guys truly realize the stature of Cell - alas, if RVX is not already moving forward with a trial, the Cell publication means as much as the promise of money in Oct from the Sheikh Abdulgader Aboud Baeshen.